GlassScriptPhysician profile
Isidoro Zarco
NPI 1710903141
$11,618.77
in general payments reported to CMS, 2019-2025
27 companies · $3,029 in 2025
The $3,029 reported for 2025 was more than what 91% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,795 · 2020: $784 · 2021: $1,042 · 2022: $830 · 2023: $1,240 · 2024: $1,899 · 2025: $3,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,167.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $4,174.68 | 2019-2025 | Clareon, Clareon Panoptix Pro, Simbrinza |
| Abbvie INC. | $1,222.04 | 2022-2025 | Vuity, Lumigan, Alphagan P |
| Allergan, INC. | $1,094.59 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $955.22 | 2023-2025 | Miebo, Xiidra, Infuse |
| Aerie Pharmaceuticals, INC. | $785.31 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $692.74 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $642.42 | 2019-2025 | |
| New World Medical,INC. | $329.83 | 2023-2025 | Ahmed Glaucoma Valve, Streamline, Via360 |
| Novartis Pharmaceuticals Corporation | $257.28 | 2019-2023 | |
| Kala Pharmaceuticals, INC. | $254.87 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $246.26 | 2019 | |
| Eyevance Pharmaceuticals LLC | $154.79 | 2019-2020 | |
| Dompe US, INC. | $147.51 | 2024 | Oxervate |
| Omeros Corporation | $125.00 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $98.71 | 2024-2025 | Xdemvy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $93.49 | 2021-2022 | |
| Amgen INC. | $57.16 | 2024 | Tepezza |
| Thea Pharma INC. | $48.72 | 2024-2025 | Iyuzeh |
| Carl Zeiss Meditec USA, INC. | $44.10 | 2025 | Cirrus Hd-Oct |
| Oyster Point Pharma, INC. | $39.50 | 2023-2024 | Tyrvaya |
| Harrow Eye, LLC | $37.60 | 2025 | Vevye |
| Biotissue Holdings INC. | $30.75 | 2020-2024 | |
| Rayner Intraocular Lenses Limited | $22.35 | 2024 | Rayone Spheric, Omidria, Rayone Aspheric |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $16.11 | 2019 | |
| Alimera Sciences, INC. | $14.76 | 2022 | |
| Akorn, INC. | $13.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isidoro Zarco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.